glp 1 for perimenopause weight gain GLP-1s and the Menopause: What you need to know Weight gain during perimenopause &

BPC-157 is not FDA-approved and is not commercially available as a licensed pharmaceutical product in most countries

When to schedule a visit You may benefit from a medical weight loss visit if: Your insurance denied Wegovy, Zepbound, or another GLP-1 medication You are not sure why your medication was denied or what to do next You want to know whether an appeal makes sense for your specific situation You want to compare GLP-1 medication options and figure out which is most likely to be covered under your plan You want to discuss cash-pay or manufacturer-program options You want help building a realistic, documented medical weight loss plan You have obesity along with insulin resistance, prediabetes, high cholesterol, hypertension, PCOS, sleep apnea, or perimenopausal weight gain You suspect mood, hormones, or sleep issues might be driving more of the weight gain than diet alone Frequently asked questions Why was my Wegovy or Zepbound denied if I meet the BMI cutoff

The goal will be to address the risk of malnutrition and the loss of lean muscle mass while on the GLP-1 therapy and to avoid or limit weight rebound after the therapy

STEP 1 (Wilding et al